|
2
|
Babu M, Durga Devi T, Mäkinen P, Kaikkonen M, Lesch HP, Junttila S, Laiho A, Ghimire B, Gyenesei A, Ylä-Herttuala S. Differential Promoter Methylation of Macrophage Genes Is Associated With Impaired Vascular Growth in Ischemic Muscles of Hyperlipidemic and Type 2 Diabetic Mice: Genome-Wide Promoter Methylation Study. Circ Res 2015; 117:289-99. [PMID: 26085133 DOI: 10.1161/circresaha.115.306424] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2015] [Accepted: 06/17/2015] [Indexed: 12/18/2022]
Abstract
RATIONALE Hyperlipidemia and type 2 diabetes mellitus (T2DM) severely impair adaptive vascular growth responses in ischemic muscles. This is largely attributed to dysregulated gene expression, although details of the changes are unknown. OBJECTIVE To define the role of promoter methylation in adaptive vascular growth in hyperlipidemia (LDLR(-/-)ApoB(100/100)) and T2DM (IGF-II/LDLR(-/-)ApoB(100/100)) mouse models of hindlimb ischemia. METHODS AND RESULTS Unilateral hindlimb ischemia was induced by ligating femoral artery. Perfusion was assessed using ultrasound, and capillary and arteriole parameters were assessed using immunohistochemistry. Genome-wide methylated DNA sequencing was performed with DNA isolated from ischemic muscle, tissue macrophages (Mϕs), and endothelial cells. Compared with the controls, hyperlipidemia and T2DM mice showed impaired perfusion recovery, which was associated with impaired angiogenesis and arteriogenesis. Genome-wide proximal promoter DNA methylation analysis suggested differential patterns of methylation in Mϕ genes in ischemic muscles. Classically activated M1-Mϕ gene promoters, including Cfb, Serping1, and Tnfsf15, were significantly hypomethylated, whereas alternatively activated M2-Mϕ gene promoters, including Nrp1, Cxcr4, Plxnd1, Arg1, Cdk18, and Fes, were significantly hypermethylated in Mϕs isolated from hyperlipidemia and T2DM ischemic muscles compared with controls. These results combined with mRNA expression and immunohistochemistry showed the predominance of proinflammatory M1-Mϕs, compared with anti-inflammatory and proangiogenic M2-Mϕs in hyperlipidemia and T2DM ischemic muscles. CONCLUSIONS We found significant promoter hypomethylation of genes typical for proinflammatory M1-Mϕs and hypermethylation of anti-inflammatory, proangiogenic M2-Mϕ genes in hyperlipidemia and T2DM ischemic muscles. Epigenetic alterations modify Mϕ phenotype toward proinflammatory M1 as opposed to anti-inflammatory, proangiogenic, and tissue repair M2 phenotype, which may contribute to the impaired adaptive vascular growth under these pathological conditions.
Collapse
Affiliation(s)
- Mohan Babu
- From the Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (M.B., T.D.D., P.M., M.K., H.P.L., S.Y.-H.); Finnish Microarray and Sequencing Centre, Turku Centre for Biotechnology, Turku, Finland (S.J., A.L., B.G., A.G.); and Science Service Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland (S.Y.-H.)
| | - Thota Durga Devi
- From the Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (M.B., T.D.D., P.M., M.K., H.P.L., S.Y.-H.); Finnish Microarray and Sequencing Centre, Turku Centre for Biotechnology, Turku, Finland (S.J., A.L., B.G., A.G.); and Science Service Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland (S.Y.-H.)
| | - Petri Mäkinen
- From the Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (M.B., T.D.D., P.M., M.K., H.P.L., S.Y.-H.); Finnish Microarray and Sequencing Centre, Turku Centre for Biotechnology, Turku, Finland (S.J., A.L., B.G., A.G.); and Science Service Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland (S.Y.-H.)
| | - Minna Kaikkonen
- From the Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (M.B., T.D.D., P.M., M.K., H.P.L., S.Y.-H.); Finnish Microarray and Sequencing Centre, Turku Centre for Biotechnology, Turku, Finland (S.J., A.L., B.G., A.G.); and Science Service Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland (S.Y.-H.)
| | - Hanna P Lesch
- From the Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (M.B., T.D.D., P.M., M.K., H.P.L., S.Y.-H.); Finnish Microarray and Sequencing Centre, Turku Centre for Biotechnology, Turku, Finland (S.J., A.L., B.G., A.G.); and Science Service Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland (S.Y.-H.)
| | - Sini Junttila
- From the Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (M.B., T.D.D., P.M., M.K., H.P.L., S.Y.-H.); Finnish Microarray and Sequencing Centre, Turku Centre for Biotechnology, Turku, Finland (S.J., A.L., B.G., A.G.); and Science Service Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland (S.Y.-H.)
| | - Asta Laiho
- From the Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (M.B., T.D.D., P.M., M.K., H.P.L., S.Y.-H.); Finnish Microarray and Sequencing Centre, Turku Centre for Biotechnology, Turku, Finland (S.J., A.L., B.G., A.G.); and Science Service Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland (S.Y.-H.)
| | - Bishwa Ghimire
- From the Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (M.B., T.D.D., P.M., M.K., H.P.L., S.Y.-H.); Finnish Microarray and Sequencing Centre, Turku Centre for Biotechnology, Turku, Finland (S.J., A.L., B.G., A.G.); and Science Service Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland (S.Y.-H.)
| | - Attila Gyenesei
- From the Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (M.B., T.D.D., P.M., M.K., H.P.L., S.Y.-H.); Finnish Microarray and Sequencing Centre, Turku Centre for Biotechnology, Turku, Finland (S.J., A.L., B.G., A.G.); and Science Service Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland (S.Y.-H.)
| | - Seppo Ylä-Herttuala
- From the Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland (M.B., T.D.D., P.M., M.K., H.P.L., S.Y.-H.); Finnish Microarray and Sequencing Centre, Turku Centre for Biotechnology, Turku, Finland (S.J., A.L., B.G., A.G.); and Science Service Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland (S.Y.-H.).
| |
Collapse
|